European Commission clears Zimmer's proposed acquisition of Biomet

Zimmer Holdings, Inc. (NYSE and SIX: ZMH) ("Zimmer") announced today that the European Commission ("EC") has conditionally cleared Zimmer's proposed acquisition of Biomet, Inc. ("Biomet"). The EC's clearance is conditioned upon Zimmer entering into agreements with a suitable buyer to divest certain assets comprising the remedy package previously submitted to the EC. Zimmer expects to enter into such agreements in the near term. As previously announced, the proposed transaction also received clearance from the Japan Fair Trade Commission.

The transaction remains subject to clearance by the U.S. Federal Trade Commission, as well as other customary closing conditions.

Zimmer noted that it is pleased with and encouraged by the progress to date with the overall regulatory process and expects to close the transaction in April 2015.

Under the terms of the merger agreement announced on April 24, 2014, Zimmer will acquire Biomet in a cash and stock transaction valued at approximately $13.35 billion, including the assumption of net debt.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Non-Hispanic Black children and low-income youth disadvantaged in concussion care